Sitemap
87 articlesA complete index of every article on this site.
Biotech
- NIH Completes Phase 1 Trial of AAV2-GDNF Gene Transfer Infused Into the Brain for Advanced Parkinson's Disease
- NIH Marks First-in-Human Intrathecal AAV9 Gene Transfer Trial for Giant Axonal Neuropathy Complete
- AbCellera-Jazz TCE Deal: The Option-and-License Architecture Behind $792M Per Program
- Engineering T Cells to Hunt TP53 and RAS Mutations in Blood Cancers
- One Injection, Two Payloads: A Dual-Action AAV Gene Therapy Enters Glioblastoma Trials
- An mRNA Fix for White Blood Cells: NIH Tests Transient Gene Correction in Chronic Granulomatous Disease
- A Self-Amplifying RNA Cancer Vaccine Targets Two Hidden Proteins on Triple-Negative Breast Cancer
- A CRISPR-in-the-Eye Trial Aims to Silence a Mutant RHO Gene Causing Blindness
- Alnylam Takes RNAi Into Solid Tumors: Inside the ALN-BCAT Phase 1 in Liver Cancer
- Claim Teardown: Janssen's New Psoriasis Patent Builds the Head-to-Head Win Against Secukinumab Into the Claims
- Claim Teardown: Sanofi Lands a U.S. Patent on a Low-Viscosity Subcutaneous Isatuximab Formulation
- Measure Up 2: A JAK Inhibitor's Numbers in Moderate-to-Severe Eczema
- A Small Trial Asks a Sharp Question: Do SGLT2 Inhibitors Help Heart-Failure Patients on Mechanical Pumps?
- REScUE: When Crohn's Patients Lose Response to Ustekinumab, Does Doubling the Dose Help?
- HAVEN 5: Emicizumab Drops the Annual Bleed Rate From 53 to Under 3
- SERENITY I: A Sublingual Sedative's Two-Hour Test in Schizophrenia Agitation
- One Infusion, A New Factor IX: Inside the Phase 3 Gene Therapy Trial for Hemophilia B
Biotech IP
- A claim that must both reduce the dose and put it back
- Stryker's Pending Claims Cover a GAN That Draws the Tissue's Future
- Edwards application claims implanting a heart valve entirely between the annulus and the STJ
- When the Abstract and the Claims Disagree: Reading Regeneron's GLP1R-Tethered GDF8 Conjugate Application
- Claiming a Brain Interface Reached Through the Subarachnoid Space
- Claiming a Posture Mismatch as the Sign of a Shifted Implant
- A Self-Diagnostic Claim for Energy-Harvesting Implants
- The Electrode-Length Limitation at the Center of a Pending Pulsed-Field-Ablation Tip Claim
- A Granted Claim on an Implantable Lead Whose Fixation Mechanism Fills a Sacral Foramen
- What the Graphene-FET Sensor-Chip Application Published This Week Actually Claims
- Federal Circuit Affirms Enanta '953 Patent Anticipated: A One-Carbon Gap Broke the July 2020 Priority Date
- What Canon's Newly Granted X-Ray Detector Patent Actually Claims
- CPC Class C12N, Explained: The Patent Classification Behind CRISPR, Vectors, and Genetic Engineering
- The Biologics Patent Dance, Explained: How 42 U.S.C. 262(l) Structures Biosimilar Patent Disputes
- Who Owns the CRISPR Patents? Inside the UC–Broad Priority Dispute and Where the Record Stands
- How a Paragraph IV ANDA Challenge Works: The Certification That Starts the Hatch-Waxman Clock
- What Is a Patent Term Extension? How 35 U.S.C. 156 Adds Time Back for Regulatory Review
- The Myriad Ruling, Explained: Why Isolated Human Genes Are Not Patent-Eligible — but cDNA Can Be
- Why Diagnostic Method Patents Fail Section 101: Mayo, the Eligibility Test, and What the Law Actually Says
- What Intuitive Surgical's Newly Published Force-Sensing Instrument Application Actually Claims
- Freedom-to-Operate: The White Space Left in GLP-1 Formulation Patents
- Claim Teardown: Why the Linker Is the Whole Claim in an Antibody-Drug Conjugate
- Expiry & Exclusivity: How Vertex's CFTR Patent Layers Stack — and When They Don't
- Landscape Report: Who Owns the C07K Antibody-Engineering Record
- Landscape Report: The Lipid-Nanoparticle Delivery Estate Behind Every mRNA Drug
- Landscape Report: What CRISPR's C12N Filing Record Says About the Platform War
- Genus vs. Species: From Dual to Triple Agonists, How the Incretin Claims Are Widening
- Genus vs. Species: How Broad Are the Anti-VEGF Antibody Claims, Really?
- Thicket or Moat: Auditing Novo Nordisk's GLP-1 Patent Estate
- Claim Teardown: What Lilly's GIP/GLP-1 Co-Agonist Patents Actually Cover
- Claim Teardown: Vertex's 2025 Beta-Globin Editing Claims for Hemoglobinopathies
- Claim Teardown: The Deaminase Limitation at the Heart of the Base-Editor Patents
- Claim Teardown: The Truncated-Guide-RNA Limitation That Buys CRISPR Its Specificity
- Expiry & Exclusivity: Why the 2025 Editing Grants Outlast the First Products They Protect
- Landscape Report: The 2025 ADC Linker-Payload Estate Is the Field's Battleground
- Claim Teardown: GeneQuantum's 2025 Glycan-Remodeled Site-Specific Conjugation
- Claim Teardown: Penn's 2025 Nucleoside-Modified mRNA Vaccine for Hepatitis C
- Claim Teardown: The Dual-Cleavage Linker in a 2025 Antibody-Drug Conjugate Grant
- Claim Teardown: AstraZeneca's 2024 GLP-1-Ligand-Conjugated Oligonucleotide
- Landscape Report: The 2024 AAV-Capsid Estate Is Where Gene-Therapy Delivery Is Fought
- Claim Teardown: The Dual-Strand Limitation in Broad's 2024 Prime-Editing Grants
- Claim Teardown: MIT's PASTE and the Programmable-Integration Limitation
- Claim Teardown: Agilent's 2024 Chemically-Modified pegRNA Claim for Prime Editing
- Claim Teardown: A 2024 PKP2 Gene-Therapy Grant and the Transgene-Plus-Vector Claim
- Claim Teardown: Gilead's 2023 Small-Molecule GLP-1R Modulators Break the Peptide Mold
- Claim Teardown: The EpCAM-Targeting Limitation in a 2023 CAR-T Grant
- Claim Teardown: Moderna's 2023 Herpes-Vaccine Grant Shows the Platform Beyond COVID
- Landscape Report: The 2023 CAR-T Estate Spans Pharma, Academia, and China
- Landscape Report: Organ-Selective Lipid Nanoparticles Open a New 2023 Sub-Estate
- Claim Teardown: What Legend Biotech's 2023 Chimeric Antigen Receptor Claim Recites
- Claim Teardown: Avidity's 2022 Antibody-Oligonucleotide Conjugate for Muscular Dystrophy
- Genus vs. Species: How a 2022 BCMA T-Cell Engager Narrows the Bispecific Genus
- Landscape Report: The 2022 Base-Editing Estate Was Owned Upstream
- Claim Teardown: Beam's 2022 Base-Editor Claim for Treating Hemoglobinopathies
- Claim Teardown: Engineering the PAM - The Limitation That Expands Where Cas9 Can Cut
- Claim Teardown: Roche's Protease-Activated Bispecific and the Conditional-Activity Limitation
- Claim Teardown: The Nucleobase-Editor Claims at the Root of the Base-Editing Estate
- Genus vs. Species: How a 2021 Oral-Delivery Patent Narrows the GLP-1 Genus
- Landscape Report: The Incretin-Peptide Estate Was Already a Crowd in 2021
- Expiry & Exclusivity: A 2021 mRNA Tumor-Suppressor Grant and the Term Clock on Platform Patents
- Claim Teardown: What Translate Bio's 2021 LNP-for-mRNA Claims Actually Cover
- Claim Teardown: The Triple-Agonist Conjugate Behind the Next Wave of Metabolic Peptides
- Landscape Report: Who Owned the Lipid-Nanoparticle Delivery Estate in 2021
- Claim Teardown: Amgen's 2021 GLP-1-Agonist-to-GIPR-Antagonist Conjugate Inverts the Logic
- Freedom-to-Operate: The Epigenetic-Editing White Space a 2020 Methylation Patent Marks
- Landscape Report: The 2020 RNA-Guided Editing Grants Were Already a Thicket
- Expiry & Exclusivity: How 2020 Anti-VEGF Combination Grants Extend a Franchise's Useful Life
- Claim Teardown: The Homologous-Recombination Limitation in a 2020 CRISPR Editing Grant
- Genus vs. Species: When an Anti-VEGF Patent Claims the Formulation, Not the Antibody
- Claim Teardown: How RNA-Guided FokI Nucleases Buy Specificity in the Early CRISPR Estate